Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanghuangporus baumii
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital, Anhui Medical University
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Sanghuangporus baumii is a medicinal mushroom (fungus) belonging to the Sanghuang group, traditionally utilized in Chinese medicine for its immunomodulatory and anti-tumor properties. It is currently being developed as an oral tablet formulation for the treatment of chemotherapy-induced immunodeficiency, specifically in patients with colorectal cancer who exhibit a low CD4/CD8 ratio. The drug's active constituents, including polysaccharides, flavonoids, and triterpenes, are believed to enhance T-cell immune function and promote the recovery of immune indices. A Phase 4 randomized clinical trial is evaluating its efficacy and safety compared to thymalfasin (thymosin alpha-1) in restoring immune balance following chemotherapy.
- Other names
- SanghuangporusbaumiiSanghuang mushroom
02
Targets
PRR (Pattern recognition receptors)Sucrase-Isomaltase
Beyond the preview
Go deeper on Sanghuangporus baumii.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanghuangporus baumii.